Nasal allergen‐neutralizing antibodies correlate closely with tolerated intranasal allergen challenge dose following grass pollen subcutaneous immunotherapy in patients with local allergic rhinitis

Documenti analoghi

• Early expansion of allergen‐responsive LAP+ B regulatory cells in allergic rhinitis but not in allergic asthma subjects during allergen immunotherapy
  di: Astrid L. Voskamp, et al.
  Pubblicazione: (2024)
• Treatment of allergic rhinitis with allergen immunotherapy in children and adolescents—Adherence, rhinitis severity, and asthma onset
  di: Anna M. Hedman, et al.
  Pubblicazione: (2026)
• Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy
  di: Sviatlana Starchenka, et al.
  Pubblicazione: (2024)
• Reply to correspondence: “The effectiveness of pollen allergen immunotherapy on allergic rhinitis over 18 years: A national cohort study in Denmark”
  di: Peter Bager, et al.
  Pubblicazione: (2024)
• Investigation of the diagnostic accuracy of basophil activation test for allergic phenotypes of rhinitis
  di: Almudena Testera‐Montes, et al.
  Pubblicazione: (2024)